HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

KVUE

Kenvue Inc. (S&P 500)

Consumer Defensive — Household & Personal Products

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

None 12 analysts
$17.22
$-0.44 (-2.49%)
Target: $19.50 (13.2%)

Price History

52-Week Range
Sign in to add KVUE to a watchlist or set price alerts.

Fundamentals

Market Cap$33.08B
P/E Ratio (TTM)20.26
Forward P/E13.89
EPS (TTM)$0.85
Dividend Yield4.76%
Profit Margin10.76%
Revenue Growth3.00%
ROE15.58%
Debt/Equity81.62
Recommendation None
Analyst Target$19.50
Analysts12
Next Earnings Aug 6, 2026 BMO
Indexes S&P 500

Technical Indicators

RSI (14)35.3
Beta0.43
SMA 20$17.90
SMA 40$18.49
52-Week High$20.13
52-Week Low$14.02
50-Day Avg$18.71
200-Day Avg$18.03
Avg Volume$22.04M
Volume$20.68M

Performance Analysis

NEUTRAL

KVUE presents a mixed picture with both positive and negative indicators.

~ Trading at 52% of its 52-week range.
~ RSI at 35.3 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
~ Modest revenue growth of 3.0% year-over-year.
~ Wall Street consensus is "none" from 12 analysts.
+ Average analyst target of $19.50 implies 13.2% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Oct 01, 2026 21:01 UTC

Back to Screener Export Report